Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
AssigneeGEMoaB Monoclonals GmbH
InventorsMichael Bachmann, Armin Ehninger
Life of this patent
Estimating the term…
Abstract
The present invention relates to immune cell-based anti-cancer therapeutics and methods of using the therapeutics in the treatment of cancer.
Claims9
An antibody or fragment thereof that specifically binds CD33, wherein said antibody or antibody fragment comprises a single chain variable fragment (scFV) that comprises a humanized light chain variable domain comprising the amino acid sequence of SEQ ID NO:40 and a humanized heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:41, wherein said light chain variable domain and said heavy chain variable domain are connected by a linker peptide that is about 10 to 25 amino acids in length.
Dependencies are inferred from the claim text.